ATE435655T1 - Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort - Google Patents
Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwortInfo
- Publication number
- ATE435655T1 ATE435655T1 AT02802551T AT02802551T ATE435655T1 AT E435655 T1 ATE435655 T1 AT E435655T1 AT 02802551 T AT02802551 T AT 02802551T AT 02802551 T AT02802551 T AT 02802551T AT E435655 T1 ATE435655 T1 AT E435655T1
- Authority
- AT
- Austria
- Prior art keywords
- agonistic
- antibodies
- increase
- immune response
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32800401P | 2001-10-09 | 2001-10-09 | |
| PCT/US2002/032364 WO2003049755A1 (en) | 2001-10-09 | 2002-10-09 | Enhancement of immune responses by 4-1bb-binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435655T1 true ATE435655T1 (de) | 2009-07-15 |
Family
ID=23279079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02802551T ATE435655T1 (de) | 2001-10-09 | 2002-10-09 | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7651686B2 (de) |
| EP (1) | EP1434596B1 (de) |
| AT (1) | ATE435655T1 (de) |
| AU (1) | AU2002364935A1 (de) |
| DE (1) | DE60232895D1 (de) |
| ES (1) | ES2328025T3 (de) |
| WO (1) | WO2003049755A1 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1234031B2 (de) | 1999-11-30 | 2021-11-24 | Mayo Foundation For Medical Education And Research | B7-h1, ein neuartiges immunregulierendes molekül |
| DE60232895D1 (de) * | 2001-10-09 | 2009-08-20 | Mayo Foundation | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort |
| WO2004006853A2 (en) * | 2002-07-15 | 2004-01-22 | Mayo Foundation For Medical Education And Research | Treatment and prophylaxis with 4-1bb-binding agents |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US20070253961A1 (en) * | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
| DK3428191T3 (da) * | 2004-10-06 | 2025-01-02 | Mayo Found Medical Education & Res | B7-h1 og pd-1 til behandling af renalcellekarcinom |
| US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| WO2006088464A2 (en) * | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| EP2399935A3 (de) * | 2005-02-15 | 2012-02-22 | GTC Biotherapeutics, Inc. | Anti-CD137-Antikörper als ein Agent bei der Behandlung von Krebs und Glycosylierungvarianten davon |
| ES2417147T3 (es) * | 2005-10-21 | 2013-08-06 | Revo Biologics, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| WO2007082144A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
| US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
| WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| WO2009042773A1 (en) * | 2007-09-25 | 2009-04-02 | University Of Miami | Adoptively transferred tumor-specific t cells stimulated ex vivo using herpes simplex virus amplicons |
| WO2009111315A2 (en) * | 2008-02-29 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Methods for reducing granulomatous inflammation |
| EP2279003A4 (de) * | 2008-05-01 | 2013-04-03 | Gtc Biotherapeutics Inc | Anti-cd137-antikörper als mittel zur behandlung von entzündlichen erkrankungen |
| ES2377785B2 (es) | 2010-09-08 | 2012-09-26 | Universidad Miguel Hernández De Elche | Composición farmacéutica para el tratamiento del ojo seco. |
| SG10201912092VA (en) | 2010-09-09 | 2020-02-27 | Pfizer | 4-1bb binding molecules |
| SG191781A1 (en) | 2010-12-30 | 2013-08-30 | Lab Francais Du Fractionnement | Glycols as pathogen inactivating agents |
| US20120278487A1 (en) | 2011-04-27 | 2012-11-01 | Woelfel John Harold | System and method of handling requests in a multi-homed reverse proxy |
| WO2012145825A1 (en) * | 2011-04-27 | 2012-11-01 | Perspecsys Inc. | System and method for data obfuscation in interception of communication with a cloud |
| JP5643716B2 (ja) * | 2011-05-31 | 2014-12-17 | 楽天株式会社 | 情報処理システム、情報処理方法、情報処理装置、情報処理端末、プログラム及び記録媒体 |
| BR112015019348A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária |
| AU2014217561B2 (en) | 2013-02-13 | 2018-11-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-alpha antibodies and uses thereof |
| US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US9944992B2 (en) | 2013-03-15 | 2018-04-17 | The University Of Chicago | Methods and compositions related to T-cell activity |
| US10611826B2 (en) | 2013-07-05 | 2020-04-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
| EP3470081A1 (de) | 2013-10-01 | 2019-04-17 | Mayo Foundation for Medical Education and Research | Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
| EP3171896A4 (de) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs |
| KR20170109582A (ko) * | 2015-02-06 | 2017-09-29 | 히트 바이오로직스, 인코퍼레이티드 | 벡터 공동 발현 백신 및 공동 자극 분자 |
| AU2016219772A1 (en) | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
| US10953045B2 (en) * | 2015-04-02 | 2021-03-23 | Cancure Limited | Agents and compositions for eliciting an immune response |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
| MA46721A (fr) * | 2016-11-07 | 2019-09-11 | Advaxis Inc | Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 |
| JP6609724B1 (ja) | 2017-01-06 | 2019-11-20 | ユーティレックス カンパニー リミテッド | 抗ヒト４−１ｂｂ抗体およびその使用 |
| JP7132232B2 (ja) | 2017-02-24 | 2022-09-06 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
| JP7297672B2 (ja) | 2017-04-13 | 2023-06-26 | アジェナス インコーポレイテッド | 抗ｃｄ１３７抗体およびその使用方法 |
| WO2019005638A2 (en) * | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | ANTI-4-1BB ANTIBODIES AND METHODS OF PREPARATION AND USE |
| EP3652209A2 (de) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonistische antikörper zur bindung von humanem cd137 und verwendungen davon |
| JP6743320B1 (ja) | 2017-08-01 | 2020-08-19 | イーライ リリー アンド カンパニー | 抗ｃｄ１３７抗体 |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| EP3713961A2 (de) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung |
| WO2019109238A1 (en) * | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 antibodies and uses thereof |
| EP3744734A1 (de) | 2018-01-22 | 2020-12-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-4-1bb-antikörper, antigenbindendes fragment davon und medizinische verwendungen davon |
| KR102432046B1 (ko) | 2018-03-23 | 2022-08-12 | 일라이 릴리 앤드 캄파니 | 항-pd-l1 항체와의 조합을 위한 항-cd137 항체 |
| CA3116412A1 (en) | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| EP3873540A4 (de) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | Verfahren und materialien zur behandlung von krebs |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| WO2020231809A1 (en) | 2019-05-10 | 2020-11-19 | Lyvgen Biopharma Co., Ltd. | Humanized anti-cd137 antibodies and uses thereof |
| US20230048719A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
| US20230048361A1 (en) | 2019-12-31 | 2023-02-16 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4257774A (en) | 1979-07-16 | 1981-03-24 | Meloy Laboratories, Inc. | Intercalation inhibition assay for compounds that interact with DNA or RNA |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6303121B1 (en) * | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| WO1994026290A1 (en) | 1993-05-07 | 1994-11-24 | Immunex Corporation | Cytokine designated 4-1bb ligand and human receptor that binds thereto |
| DE69435261D1 (de) | 1993-09-16 | 2010-02-25 | Univ Indiana Res & Tech Corp | Menschlicher rezeptor h4-1bb |
| AU5369996A (en) | 1995-03-23 | 1996-10-08 | Indiana University Foundation | Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases |
| DK0766745T3 (da) | 1995-04-08 | 2002-11-25 | Lg Chemical Ltd | Monoklonalt antistof, som er specifikt for humant 4-1BB samt cellelinje, som producerer dette |
| US5874240A (en) | 1996-03-15 | 1999-02-23 | Human Genome Sciences, Inc. | Human 4-1BB receptor splicing variant |
| ATE230801T1 (de) | 1996-10-03 | 2003-01-15 | Canon Kk | Verfahren zur detektion von zielnukleinsäure, verfahren zu ihrer quantifizierung und pyrylium- verbindungen zur chemilumineszenz-analyse |
| IL129138A0 (en) | 1996-10-11 | 2000-02-17 | Bristol Myers Squibb Co | Methods and compositions for immunomodulation |
| AU6534898A (en) | 1997-02-14 | 1998-09-08 | E.I. Du Pont De Nemours And Company | Detection of double-stranded dna in a homogeneous solution |
| KR20000034847A (ko) | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| US6734172B2 (en) * | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
| WO2000041508A2 (en) | 1999-01-15 | 2000-07-20 | Mount Sinai School Of Medicine Of The City University Of New York | Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines |
| US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| EP1259595B1 (de) | 2000-02-25 | 2007-04-04 | Immunex Corporation | Integrin antagonisten |
| US20020076409A1 (en) * | 2000-07-12 | 2002-06-20 | March Carl J. | Method for treating cancer |
| DK1326961T3 (da) * | 2000-09-15 | 2008-01-07 | Ortho Mcneil Pharm Inc | Sammensætninger og fremgangsmåder tl inducering af specifikke cytolytiske T-cellereaktioner |
| US20040247563A1 (en) * | 2000-11-02 | 2004-12-09 | Lynch David H. | Method of enhancing lymphocyte-mediated immune responses |
| US6773702B2 (en) * | 2000-12-26 | 2004-08-10 | Oxigene, Inc. | Use of combretastatin A4 and its prodrugs as an immune enhancing therapy |
| AU2002322211A1 (en) * | 2001-07-12 | 2003-01-29 | Canvac | Methods and compisitions for activation human t cells in vitro |
| DE60232895D1 (de) * | 2001-10-09 | 2009-08-20 | Mayo Foundation | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort |
| US20030223989A1 (en) | 2002-04-18 | 2003-12-04 | Pluenneke John D. | CD137 agonists to treat patients with IgE-mediated conditions |
-
2002
- 2002-10-09 DE DE60232895T patent/DE60232895D1/de not_active Expired - Lifetime
- 2002-10-09 EP EP02802551A patent/EP1434596B1/de not_active Expired - Lifetime
- 2002-10-09 US US10/492,056 patent/US7651686B2/en not_active Expired - Lifetime
- 2002-10-09 WO PCT/US2002/032364 patent/WO2003049755A1/en not_active Ceased
- 2002-10-09 AT AT02802551T patent/ATE435655T1/de not_active IP Right Cessation
- 2002-10-09 ES ES02802551T patent/ES2328025T3/es not_active Expired - Lifetime
- 2002-10-09 AU AU2002364935A patent/AU2002364935A1/en not_active Abandoned
-
2009
- 2009-11-06 US US12/614,150 patent/US8163550B2/en not_active Expired - Fee Related
-
2012
- 2012-03-21 US US13/426,151 patent/US8772026B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20120225043A1 (en) | 2012-09-06 |
| ES2328025T3 (es) | 2009-11-06 |
| EP1434596B1 (de) | 2009-07-08 |
| EP1434596A1 (de) | 2004-07-07 |
| AU2002364935A1 (en) | 2003-06-23 |
| US7651686B2 (en) | 2010-01-26 |
| DE60232895D1 (de) | 2009-08-20 |
| WO2003049755A1 (en) | 2003-06-19 |
| US20100266611A1 (en) | 2010-10-21 |
| US20050013811A1 (en) | 2005-01-20 |
| US8772026B2 (en) | 2014-07-08 |
| US8163550B2 (en) | 2012-04-24 |
| EP1434596A4 (de) | 2004-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60232895D1 (de) | Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort | |
| ATE255420T1 (de) | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung | |
| GT200800132A (es) | Anticuerpos anti-il-23 humanos, composiciones, metodos y usos | |
| ATE500323T1 (de) | Subtilisin-variante | |
| DK1525320T3 (da) | Fremgangsmåde til ekspression af rekombinant protein i CHO-celler | |
| NO20083160L (no) | Methods for obtaining immortalized anitbody secreting cells | |
| DK1140173T3 (da) | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf | |
| ATE172743T1 (de) | Nachweis von kollagenabbau -i(in vivo) | |
| TR200602095T2 (tr) | Hümanize Anti-LT-Beta-R antikorları | |
| TR200003181T2 (tr) | Gelişmiş çoğaltılabilirliğe sahip FAP alfa'ya özgü antikor | |
| DK1650307T3 (da) | Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer | |
| TR199902818T2 (xx) | Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler. | |
| LTPA2005005I1 (lt) | Antikūnai prieš VEGF | |
| DK1395669T3 (da) | Matriks bindingsregioner og fremgangsmåder til anvendelse af disse | |
| ATE402188T1 (de) | Bindungsproteine als biosensoren | |
| DK1699822T3 (da) | IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf | |
| CY1112993T1 (el) | Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1 | |
| DK1492869T3 (da) | Transplantataccept-inducerende celler af monocytisk oprindelse, deres fremstilling og anvendelse | |
| ATE400289T1 (de) | Verwendung vom vaskulären endothelialen wachstumsfaktor 2 (vegf-2) | |
| CY1111371T1 (el) | Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο | |
| JO3244B1 (ar) | بروتينات ربط مستضادات il – 23 البشرية | |
| ATE328079T1 (de) | Neues gen mit einem revers-transkriptase-motiv | |
| ATE132162T1 (de) | Humane gammainterferonantagonisten | |
| EA200200974A1 (ru) | Моноклональные антитела к рецептору лпнп человека, их получение и применение | |
| DK1456238T3 (da) | Produktion af F(ab')2-fragmenter i pattedyrceller |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |